Drug intelligence / Profile preview

C-82

Development stage: Unknown
Lead developer: PRISM BioLab
Modality: Small Molecules
Administration: Topical[4]

Overview

C-82 is a small molecule drug that acts as an inhibitor of CREBBP (cAMP-response element binding protein binding protein) and CTNNB1 (Catenin beta 1). It was initially developed by PRISM BioLab. The compound is a prodrug of PRI-724 and is being investigated for its potential to modulate Wnt/β-catenin signaling pathways, which are implicated in fibrotic diseases and certain cancers. Clinical development has focused on topical formulations for conditions such as systemic sclerosis (scleroderma), CREST syndrome, and plaque psoriasis[3][4].

Other names: C 82C82C-82

Targets

CREBBP (CREB-binding protein)

Beyond the preview

Go deeper on C-82.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-82.

Explore the full profile